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ABSTRACT
CRISPR-Cas9 Transfection Optimization and use in a Forward Genetic Screen
to Identify Telomere Length Maintenance Genes
Kelsey Phillips
Department of Physiology and Developmental Biology, BYU
Master of Science
Mutations in the telomere length maintenance pathway can lead to a spectrum of diseases
called telomere syndromes, however, the pathway is not fully understood and there may still be
unknown components. We designed a forward genetic screen to identify new genes involved in
telomere length maintenance. Of the top ranked genes, ZNF827, a zinc finger protein, is the most
promising candidate gene. The possible discovery of a new component involved in telomere
length maintenance increases our understanding of the pathway and opens new avenues of
research. Recent advances in molecular biology techniques, such as the use of RNA-guided
nuclease CRISPR associated protein 9 (Cas9), have made screens like this possible. Cas9 is a
nuclease that uses a guide RNA(gRNA) to direct its endonuclease activity. The use of Cas9 has
revolutionized the field of genome engineering, providing scientists with more efficient methods
to knockout and modify genomes. We sought to optimize CRISPR-Cas9 genome editing to make
it as widely accessible as possible. We compared plasmid, ribonucleoprotein (RNP), and RNA
only lipid-mediated transfection of CRISPR-Cas9 into cell lines using a novel reporter system to
measure genome editing efficiency. All methods were successful to some extent, however, RNP
lipofection was the most efficient and has many advantages over other methods. We also found
that short homology arms of 30-35bp on donor templates was able to mediate site specific
editing. These methods should broaden the accessibility of CRISPR-Cas9 genome editing.
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INTRODUCTION
Telomeres are long nucleotide repeats that cap the ends of chromosomes and are thought
to play a role in molecular aging. Telomere dysfunction has been linked to many degenerative
disorders including pulmonary fibrosis (Armanios and Blackburn, 2012; Armanios et al., 2005;
Armanios et al., 2007). Incidence of pulmonary fibrosis is increasing worldwide, yet there is still
a lack of promising treatment options (Hutchinson et al., 2015; Hutchinson et al., 2014). Further
understanding of the role of telomeres in the development and progression of pulmonary fibrosis
is necessary for future studies into the molecular causes of the disease as well as possible
treatments.
Telomeres protect the ends of chromosomes by binding a group of proteins collectively
known as shelterin. The shelterin complex prevents the ends of chromosomes from being seen as
double stranded breaks in the DNA and suppresses the DNA damage response (de Lange, 2010;
Doksani and de Lange, 2014). The shelterin complex is made up of 6 different proteins: TRF1,
TRF2, TIN2, TPP1, POT1, and RAP1 (de Lange, 2005; Lackner et al., 2011)(Figure 1B). The
loss of shelterin components results in a DNA damage response and subsequent senescence or
apoptosis (Lackner et al., 2011).
With cell replication, telomeres shorten and over successive rounds of cell division
eventually reach a critical length and can no longer block the DNA damage response. In this way
telomeres function as a biological clock and are thought to play a role in aging and age-related
diseases. Telomerase can elongate telomeres to prevent telomere shortening over many cell
divisions (Blackburn et al., 1989; Greider and Blackburn, 1985; Schmidt and Cech, 2015). The
telomerase enzyme is composed of a catalytic reverse transcriptase, TERT, and an RNA
template, telomerase RNA (TR) (Figure 1A). TR contains the complimentary sequence to the
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Figure 1: Telomerase Holoenzyme and Telomere Related Proteins. A) Telomerase holoenzyme
including the protein component TERT and RNA component TR as well as Nhp2, Nop10, Dyskerin,
and NAF1. B) Shelterin components. TRF1 and TRF2 are shown binding double stranded telomere
sequence. POT1 binds single stranded telomere sequence. RAP1 associates with TRF2, TIN2 binds
TRF1 and TPP1, which in turn bind POT1. C) Other telomere related proteins RTEL1, PARN, and
TCAB1.

telomeric sequence and allows telomerase to add new nucleotides to the end of chromosomes by
reverse transcription (Armanios and Blackburn, 2012; Schmidt and Cech, 2015). Telomerase is
only active in select cells within our body such as stem cells that need to maintain high
proliferative potential and thus keep regenerative capacity after many rounds of cell division.
Mutations that prevent telomerase from elongating telomeres can cause a spectrum of
diseases called the telomere syndromes. Although the clinical manifestations of the disorders
vary, they are all caused by shortened telomeres (Armanios, 2009; Armanios and Blackburn,
2012). The most common presentation of the telomere syndromes is pulmonary fibrosis (Alder et
al., 2008; Armanios and Blackburn, 2012; Armanios et al., 2007). Pulmonary fibrosis was first
linked to telomeres when mutations in telomerase (TERT and TR) were found in families with
pulmonary fibrosis (Armanios et al., 2007). Since that time mutations in DCK1, RTEL1, PARN,
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TIN2, NOP10, NHP2, and NAF1 have all been found in patients with pulmonary fibrosis (Alder
et al., 2015; Martinez and Blasco, 2017; Stanley et al., 2016; Stuart et al., 2015) (Table 1).
Familial pulmonary fibrosis is a genetic disorder that displays autosomal dominant
inheritance (Borie et al., 2015; Planas et al., 2017). Mutations in telomerase components or other
telomere related proteins currently account for 25% of familial pulmonary fibrosis cases (Alder
et al., 2011; Alder et al., 2015; Fingerlin et al., 2013; Hoffman et al., 2016; Kropski et al., 2016).
Sporadic pulmonary fibrosis cases also occur in which there is no family history of pulmonary
fibrosis. It was recently discovered that 11% of patients with sporadic pulmonary fibrosis also
have mutations in telomere related genes (Petrovski et al., 2017). Additionally, 25% of patients
with sporadic pulmonary fibrosis and 37% of patients with familial pulmonary fibrosis have
telomere lengths below the 10th percentile including patients without known telomere related
mutations (Alder et al., 2008; Cronkhite et al., 2008). Short telomeres have also been associated
with a poorer prognosis and decreased survival rate following lung transplant in pulmonary
fibrosis patients (Dai et al., 2015; Newton et al., 2017).
Additionally, telomere syndromes including pulmonary fibrosis display genetic
anticipation, which means that each subsequent generation becomes symptomatic at an earlier
age (Armanios and Blackburn, 2012; Armanios et al., 2005). This is caused by mutations in
telomere related genes that prevent length maintenance of the telomeres in gametes resulting in
parents passing on shorter telomeres to their offspring (Armanios, 2012; Barbaro et al., 2016).
The shorter inherited telomere length causes disease symptoms earlier in each generation.
Together these findings highlight the important role of telomere length in the pathology of
pulmonary fibrosis.

3

Table 1: Telomere Genes Known to Cause Pulmonary Fibrosis When Mutated
Telomere Genes Known to Cause Pulmonary Fibrosis When
Mutated
Process/Complex

Gene

Telomerase Core Components

TERC
TERT

Telomerase Biogenesis
Sheltrin Component

DKC1
NOP10
NHP2
TIN2

Telomeric DNA Synthesis

RTEL1

TERC RNA Processing

PARN
NAF1

Despite these findings, the genetic basis for the majority of familial pulmonary fibrosis
cases is still unknown. One potential area for the discovery of more genes is in the telomere
length maintenance pathway. The mechanism of adding new telomere sequence is not yet fully
understood and there may be key components of the pathway that are still unknown. Finding new
genes involved with this process will allow for better diagnosis of telomere syndromes as well as
further research into causes and cures.
Discovering new genes and the role that those genes play in vivo has recently been made
more feasible through the use of the RNA-guided nuclease CRISPR associated protein 9
(Cas9)(Cong et al., 2013; Jinek et al., 2012). The clustered regularly interspaced short
palindromic repeats (CRISPR)-Cas system was isolated from bacteria, where it plays an
important role in adaptive immunity (Bhaya et al., 2011; Makarova et al., 2015). Cas9 is a site-
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specific endonuclease that uses a guide RNA (gRNA) complimentary to the cut site in the
genomic DNA (Bhaya et al., 2011). The double stranded break created by Cas9 can be repaired
by non-homologous end joining (NHEJ) or homology directed repair (HDR) as seen in figure 2
(Chapman et al., 2012; Ran et al., 2013). NHEJ often results in small insertions or deletions that
can disrupt the coding sequence of the gene and knockout protein function (Chang et al., 2017).
Homology directed repair uses a DNA template to repair the cut site and is less error prone than
NHEJ (Bibikova et al., 2001; Jasin and Rothstein, 2013).

Figure 2: Cas9 Cutting and Repair. Cas9 associates with a gRNA which directs Cas9 to bind at a specific
place in the genome. Cas9 then creates a double stranded cut in the DNA which can be repaired by
the cell in one of two ways. 1) Non-homologous end joining (NHEJ)- The cell repairs the break by
annealing the broken ends back together, which often results in small insertions or deletions called
“indels”. These indels may result in non-functional proteins leading to gene knock out. 2) Homology
Directed Repair (HDR)- The cell can use a template with homology to repair the break. This results in
precise genome editing.
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Both repair pathways can be utilized to study genes of interest. NHEJ can be used to
knockout genes and HDR can be used to introduce new DNA sequence into a cut site (Sander
and Joung, 2014). Addition of exogenous DNA is done by creating templates that include
homology around the Cas9 cut site and the new DNA sequence you want to introduce (Mali et
al., 2013).
Using Cas9 for genome editing has made studying the function of proteins much more
effective. There are multiple techniques available for introducing CRISPR-Cas9 into cells
including transduction, nucleofection, and transfection (Bisht et al., 2017; Dow et al., 2015; Kim
et al., 2014). Nucleofection has been shown to be effective in introducing Cas9 and its
components into cells, however, it requires specialized equipment and materials that can be
expensive and may not be available to every lab. Transduction also has limitations as the use of
virus requires extra biosafety precautions, which may not be ideal. That means that not all labs
may be able to utilize the CRISPR-Cas9 system. Because of the usefulness of CRISPR-Cas9,
there is a need to optimize its use to make it easily accessible in terms of time, money, and
materials.
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MATERIALS AND METHODS
Plasmid Construction
pSpCas9(BB)-2A-Puro (PX459) V2.0, a gift from Feng Zhang (Addgene #62988), was
used to construct Cas9 and gRNA expressing vectors according to previous published
protocols(Ran et al., 2013). pCDNA5/FRT-EGFP and -∆ATG-EGFP plasmids were constructed
using Gibson Assemblies following standard procedures. A puromycin-expression plasmid was
generated by cloning the puromycin N-acetyl-transferase gene in an SV40-expression cassette
into the pBluescript II KS(+) vector. The lentiCas9-blast plasmid, a gift from Feng Zhang
(Addgene #52962), was used to stably express Cas9 in cell lines according to previous published
protocols (Sanjana et al., 2014). The hTR-WT and MT-hTR-AU5 GFP expressing plasmids were
a kind gift from Bradley Stohrs(Stohr et al., 2010). Lentiviral plasmids carrying puromycin
resistance and coding for gRNAs designed to target TERT and ZNF827 were created by cloning
a gRNA to TERT and ZNF827 respectively into lentiGuide-Puro, a gift from Feng Zhang
(Addgene #52963). Human Brunello CRISPR knockout pooled library was a gift from David
Root and John Doench (Addgene #73178) (Doench et al., 2016b).

Cell Culture and Transfection
HeLa cells were purchased from the ATCC (Cat #CCL-2). HEK 293 FlpIn cells were
purchased from Invitrogen and both cell lines were cultured in Dulbecco’s Modified Eagle’s
medium (DMEM, Gibco) supplemented with 10% fetal bovine serum (FBS, Gibco), 0.29 mg/ml
L-Glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin (Gibco). Cells were grown in a
37°C humid incubator with 5% CO2. HEK 293 FlpIn Cells were transfected with the EGFP or
∆ATG-EGFP plasmids described above according to manufacturer’s protocols and selected with
hygromycin. Cas9 stable cell lines were generated by infecting cells with a Cas9-expressing
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lentivirus (Addgene plasmid #52962). All px459v2, RNP, and RNA only transfections were
done in 24 well plates using 1 ul of Lipofectamine 2000 (Invitrogen) as the transfection reagent.
Plasmid transfections were done using 0.5 µg of plasmid. RNP transfections used 250 ng pBS
Pur, 100 ng gRNA and 0.5 µg of cas9 purified protein. In RNP transfection Cas9 and the gRNA
were incubated at room temperature for 5 minutes prior to the addition of pBS Pur. In RNA only
transfections 250 ng pBS Pur and 100 ng of gRNA were used. Donor template concentration was
optimized for each transfection type. 500ng of template was used in plasmid transfection, 50 ng
of template was used in RNP transfections, and 10 ng of template in RNA only transfections. 24
hours after transfection 2µg/ml of puromycin was added to the cells. The cells were incubated in
puromycin for 48 hours after which the selection reagent was removed from the cells. Individual
clones of cells were isolated by limiting dilution. LOX melanoma cells were a kind gift from
Bradley Stohrs and were cultured in Roswell Park Memorial Institute (RPMI, Gibco)
supplemented with 10% fetal bovine serum (FBS, Gibco), 0.29 mg/ml L-Glutamine, 100 U/ml
penicillin, and 100 µg/ml streptomycin (Gibco).

Flow Cytometry and Microscopy
Cells were trypsinized and then neutralized using DMEM/10% FBS for HEK 293 cells
or RPMI/10% FBS for LOX cells. The cells were mixed and the percentage of cells expressing
EGFP was assessed using a BD Accuri Flow cytometer. Viable cells were gated using
morphology and EGFP percentages of the viable cells were measured. Imaging of fluorescent
proteins was performed on an Olympus IX70 microscope equipped with a MicroFire Color
camera (Olympus) using a 20x objective. Cell sorting of LOX cells was performed using a FACS
Aria Fusion. Cells were first trypsinized, rinsed, and suspended in PBS/2% FBS. The cells were
sorted for GFP and collected in RPMI/10% FBS cell culture media.
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Genomic DNA Collection, Screening, and Sequencing of Modified Clones
Genomic DNA was isolated from individual clones by suspending cells in lysis buffer
(300µl; 10mM Tris-HCL, 25mM EDTA, 0.5% SDS, pH 8), precipitating protein by addition of
salt (100µl; 5M Ammonium Acetate), and extraction of DNA with ethanol.. PCR was performed
using primers flanking the Cas9 cut site and amplicons were cloned using zero-blunt cloning
(Invitrogen). Several colonies from each cloned amplicon were Sanger sequenced to characterize
individual mutations.

Donor Template Creation
Single stranded donors for ATG and ATG-FLAG were synthesized by IDT with 30 base
pairs of homology on the 5` and 3` ends. Double stranded templates for ATG-RFP knock-in was
generated by PCR amplification and incorporated a short linker on the C-terminus of RFP and 35
base pairs of homology on either end.

Western Blots
Western blots were carried out using standard procedures. Briefly, 20-40ug of cell lysate
was separated on a 4-12% SDS-PAGE gel and transferred to nitrocellulose membranes.
Membranes were blotted with Flag (M2; Sigma), GFP (Aves Laboratories), KEAP1 (Cell
Signaling Technologies), GAPDH (Santa Cruz Biotechnology), and secondary antibodies (Licor)
and imaged on an infrared scanner (Licor).

Protein Purification
Cas9 was expressed in BL21(DE3) cells using pET-28b-Cas9-His, a gift from Alex
Schier (Addgene plasmid # 47327)(Gagnon et al., 2014). Following overnight induction with
IPTG at 18C, bacterial were harvested and lysed in lysis buffer (20mM Tris pH8, 500mM NaCl,
9

and protease inhibitors [Sigma]). Bacteria were lysed using sonication or high-pressure
microfluidic shearing and the lysate was centrifuged at 15,000g for 20 minutes. Clarified
supernatants were mixed with 2mL of Nickle Beads (BioRad) and mixed for 1 hour at 4C. The
suspension was poured into a gravity column and washed with wash buffer (20mM Tris pH8,
50mM NaCl, 25mM imidazole). Cas9 was eluted (20mM Tris pH 8, 500mM NaCl, 250mM
Imidazole) and dialyzed into storage buffer (20mM Tris pH 8, 500mM KCL, 10mM MgCl2,
50% glycerol).

In Vitro Transcription and In Vitro Cutting with Cas9
Primers were constructed containing a T7 transcription site as well as a guide RNA
sequence (see supplemental table of primers). We used the plasmid pSpCas9(BB)-2A-Puro as a
template for PCR to create a product with a T7 transcriptional start site, gRNA sequence, and
gRNA scaffold. In vitro transcription was performed with a MEGAshortscript T7 Transcription
kit (Invitrogen) per the manufacturer’s protocol. RNA was isolated using a phenol chloroform
extraction and diluted in water to 1µg/µl. The RNA was then stored in aliquots at -80°C. To test
the functionality of the RNP we performed an in vitro digestion with 200 ng target DNA, 100 ng
gRNA, 1µl BSA (NEB), 1µl NEB buffer 3, 1 µg Cas9, and water assembled into a 10 µl
reaction. This mixture was incubated at 37°C for 1 hour followed by a 10-minute incubation at
65°C. Digestion products were separated on a .75% agarose gel.

Hydrogen Peroxide Challenge
KEAP1-targeted and parental HeLa cells were cultured in a 96-well plate and exposed to
increasing concentrations of H2O2 (0-250 µM) for 24 hours. Following exposure, cell viability
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was measured using an 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide (MTT)
using previously described methods(van de Loosdrecht et al., 1994).

Viral Packaging and Transduction
Viruses were packaged in 293 FT cells in DMEM (Gibco) containing 1% FBS (Gibco).
Transfections were done using a 4:3:1 ratio of viral plasmid, to psPax2, to pMD2.G following
the lipofectamine 2000 protocol. Virus was collected 48 and 72 hours post transfection and
concentrated using centrifugal filters. Transduction was done using 8ug/ml polybrene and the
packaged virus. The media was changed the following day.

Telomerase Repeated Amplification Protocal (TRAP) Assay
TRAP assay was performed according to previously published protocol (Mender and
Shay, 2015). Briefly, 100,000 cells were collected and suspended in NP-40 solution on ice for 30
minutes. A TRAP master mix was prepared and 1ul of sample was added to each tube. Cy5
primers were used so results could be visualized by fluorescence. Amplification of the extension
products was then performed by PCR according to the published protocol. The samples were run
on a 10% non-denaturing polyacrylamide gel at 250 V. The results were visualized on a licor
imagining system.

Forward Genetic Screen
Human Brunello CRISPR knockout pooled library was a gift from David Root and John
Doench (Addgene #73178) (Doench et al., 2016b). LOX melanoma Cas9 Blast cells were first
transduced with Human Brunello CRISPR knockout pooled library (Human GPP library) at an
MOI of 3. After 48 hours the cells underwent puromycin selection. Following puromycin
selection MT-hTR-AU5 was added at an MOI of 10. After 15 days the cells were sorted for GFP
11

positive cells. The cells were then allowed to grow for two weeks before being sorted again and
collected for genomic DNA.

GeCKO PCR and Deep Sequencing
The gRNAs were amplified using a two-step PCR procedure. The first PCR was done in
4 reactions each with 5 ug of pooled genomic DNA. The thermocycling parameters for the PCR
95°C for 2 min and 18 cycles of 95°C for 20s, 65°C for 30s, and 72°C for 30s followed by 72°C
for 5 min. The second PCR added the barcodes for Illumina sequencing. The PCR products from
the first PCR were pooled and 5 ul of that was added to the second PCR. The thermocycling
parameters for the PCR 95°C for 2 min and 25 cycles of 95°C for 20s, 61°C for 30s, and 72°C
for 30s followed by 72°C for 5 min. The concentration of DNA in each barcode was quantified
using the Next Library Quantification kit (New England Biolabs, Inc.). After quantification each
sample was diluted to 10nM and mixed in equal amounts with all other samples. The pooled
samples were again quantified and then diluted to 2.5nM. The diluted libraries were then
sequenced with MiSeq instrument (Illumina).

Data Analysis
We used GraphPad Prism v7 for analysis and generation of graphs. Means were
compared using Student’s t-test. P values ≤0.05 were considered significant and all values shown
are two-sided. Data analysis of the deep sequencing data was evaluated using custom pearl
script. Bowtie was used to align the gRNAs to genes and MaGeCK was used to rank genes.
Significance for the ZNF827 verification experiment was calculated using ANOVA followed by
a TukeyHSD analysis in R.
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RESULTS
CRISPR-Cas9 Optimization

RNP Lipofection Showed Highest Efficiency of Knockout
In order to make CRISPR-Cas9 more accessible, we decided to determine the most
effective method for gene knockout using cationic lipid-mediated transfection (lipofection) to
introduce Cas9 components into cells. For transfections we used an HEK 293 FlpIn cell line in
which a single copy of EGFP had been inserted into the FRT site using Flp recombinase. This
cell line allowed for easy quantification of the effectiveness of GFP knockout using flow
cytometry. We also created an HEK 293 FlpIn EGFP Cas9 clonal cell line to test RNA only
transfection into stably expressing Cas9 cells (Figure 3A). We decided to compare the knockout
efficiency of transfection of a plasmid encoding Cas9 and gRNA, a Ribonucleoprotein (RNP)
containing Cas9 and gRNA, and gRNA only into a Cas9 expressing cell line. For the plasmid
and RNP transfections we used the HEK 293 FlpIn EGFP line and for the RNA only transfection
we used the HEK 293 FlpIn EGFP Cas9 blast cell line.
For the RNP and RNA only transfections a gRNA was created through a reverse
transcriptase reaction. In order to test that the synthesized gRNA was functional, an in vitro Cas9
cutting experiment was performed (Figure 3 B). A template for cutting was created through PCR
using an EGFP plasmid. The template, gRNA, and Cas9 were incubated and then run on a
agarose gel. The template was cut in the presence of Cas9 and the gRNA indicating that the
gRNA successfully directed Cas9 cutting (Figure 3B).
In order to determine the most effective transfection reagent, we compared lipofectamine
2000, lipofectamine CRISPRmax, and lipofectamine RNAimax, and found lipofectamine 2000
transfection to be the most effective and least harmful to the cells (optimization not shown). We
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continued our experiments using lipofectamine 2000 to compare plasmid, RNP, and RNA only
transfections. After transfection, cells were allowed to grow for 5 days before GFP percentage
was measured through flow cytometry. Plasmid, RNP, and RNA only transfections all showed
some level of GFP knockout, however, without selection the levels of GFP knockout were low
(Figure 3D).
In order to increase the effectiveness of GFP knockout, we decided to co-transfect a
selection plasmid that would confer resistance to puromycin. The plasmid px459v2 already
carries resistance to puromycin, so for the RNP and RNA only transfections we co-transfected a
plasmid expressing puromycin N-acetyl-transferase (PAC) which confers resistance to
puromycin. One day after transfection, puromycin was added and the cells were left in selection
for 48 hours. The cells were passaged until 5 days after transfection when the cells were
collected for flow cytometry to measure GFP percentage. Representative flow data of a
successful RNP transfection is shown in Figure 3C. The percentage of GFP negative cells were
quantified for each condition and the results are shown in Figure 3D.
All conditions showed some level of GFP knockout which was increased with the
addition of a selection reagent showing that at least one limiting factor in successful gene editing
is transfection efficiency. Of the methods tested, RNP transfection with puromycin selection was
the most effective.
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Figure 3. Comparison of Methods to Introduce Cas9 and Guide RNAs. A) Western Blot of HEK 293 FlpIn
Lines Expressing GFP Reporter and Cas9. GFP was introduced at FlpIn locus to ensure that only a single
copy of the target gene was present; Cas9 was introduced by infecting cells with a lentivirus encoding
flag-tagged Cas9 (see materials and methods). B) In Vitro Digestion of Target DNA by RNP Complex. A
1000 base pair (bp) amplicon was generated by PCR amplification of a GFP-containing plasmid.
Digestion of the amplicon results in two 500 bp segments. C) Representative Histogram of Flow
Cytometry Data Demonstrating Disruption of GFP by Cas9. The histogram shows viable cells five days
post transfection with a GFP-specific RNP. The green line represents control cells (GFP+) and the grey
line represents GFP+ cells that had been transfected with a GFP-specific RNP. D) Quantification of the
Fraction of GFP Positive Cells Remaining After Treatment with Cas9 and gRNA Using Different Methods
of Introduction (n=3/group). Data are expressed as mean ± SEM. **P < 0.02, ***P < 0.001, and ****P <
0.0001; Student’s t-test.
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Knocking Out Endogenous Genes Using RNP Transfection
Using the conditions found to be the most effective at knocking out GFP in the HEK 293
FlpIn EGFP reporter system, we attempted to knockout endogenous genes. We designed 1-2
gRNAs targeted at the 5’ coding region for both telomerase reverse transcriptase (TERT) and
kelch like ECH associated protein 1 (KEAP1) using the Broad GPP portal design tool
(http://portals.broadinstitute.org/gpp/public/). Before transfection we tested the gRNAs through
a Cas9 in vitro digest using PCR amplified regions of the genes as templates for cutting (Figure
4A and 4B). After successful in vitro cutting, we moved to lipofection into cell lines. We decided
to use two common cell lines, HEK 293 and HeLa, to make our experiments widely applicable.
We performed RNP transfection with gRNA targeted at TERT into HEK 293 cells,
selected with puromycin, and isolated clones. Genomic DNA was collected from the clones and
PCR was performed around the Cas9 cut site in each clone to see if there were obvious band
shifts or mutations in any of the clonal cell populations. As can be seen in Figure 4C some of the
clones had obvious mutations in the cut site region of TERT. To ensure that these cells had
deleterious mutations in all of the alleles of TERT we subcloned to sequence each allele. An
example of sequencing from a knockout clone is shown in Figure 4D. We found a 1bp
frameshifting insertion in one allele and a 250bp insertion in the other allele confirming that this
cell population should have no functional TERT.
Interestingly our attempts to disrupt KEAP1 through RNP transfection in HeLa cells were
unsuccessful after numerous attempts despite the gRNA showing functionality in the Cas9 in
vitro digestion (Figure 4B). We therefore turned to plasmid transfection for the knockout of
KEAP1 using px459v2 designed to target KEAP1. After plasmid transfection, clones were
readily isolated and genomic DNA was collected. PCR of the clones was performed around the
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Cas9 cut site and many bands were seen indicating mutations in KEAP1 (Figure 4E). We again
subcloned cell populations that looked as if they had multiple mutations and sequenced
individual alleles. Figure 4G shows the sequencing of one of these clones which had a 1bp
insertion in one allele and a 1bp deletion in the other copy of KEAP1. The knockout of KEAP1
was further confirmed through western blot (Figure 4F). Additionally, we wanted to verify that
knockout of KEAP1was showing the expected physiological effect. KEAP1 is a negative
regulator of Nuclear factor (erythroid-derived 2)-like 2 (NRF2). Nrf2 is a transcription factor that
binds to the anti-oxidant response element (ARE) and turns on transcription of antioxidant
proteins (Hayes and McMahon, 2001; Katoh et al., 2005; Sihvola and Levonen, 2017). When
KEAP1 is knocked out we should see an upregulation of Nrf2 activity, which protects the cell
from cytotoxic effects of oxidants. To test this, we dosed the cells with varying degrees of H2O2
and measured the percent of cells that survived. Cells with KEAP1 knocked out showed a much
higher resistance to H2O2 confirming that the knockout of KEAP1 was having the expected
physiological effect (Figure 4G).
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Figure 4. RNP Mediated Disruption of Endogenous Genes. A) In vitro digestion of DNA Fragment
Containing Sequence Complementary to TERT gRNA Sequence. A target substrate was generated by
digestions of a plasmid containing TERT cDNA to yield a 3.6 kb product. Digestion of the product with
RNP yields a 2.8 kb and 800 bp band. B) In Vitro Digestion of Amplicon Containing KEAP1 cDNA
Sequence. A substrate was generated by PCR amplification of a 250 bp fragment containing the KEAP1targetting sequence. Digestion with KEAP1-specific RNP yields a 150 and 100 bp products. C) PCR of
Genomic DNA from TERT-Targeted Clones Showing Amplicon Size Heterogeneity in Several Clones.
Approximate primer positions shown in D. D) Schematic and Sequencing Results from One Clone
Showing Frame Shifting Mutations in 2 Out of 2 Alleles Detected. PCR products from C were sub-cloned
using zero-blunt cloning, so that individual alleles could be sequenced. 16-18 subclones were sequenced
for each independent clone. The number of alleles is inferred from the number of unique sequences that
were detected. E) PCR of Genomic DNA from KEAP1-targetted Clones Showing Amplicon Size
Heterogeneity in Several Clones. Approximate primer positions shown in G. F) Western blot for showing
loss of protein in targeted cells. G) Schematic of KEAP1 Gene and Location of gRNA. Protospacer adjacent
motif (PAM) sequence (green) and Cas9 cut site (arrow) are depicted. Note, the gRNA target sequence
was located on the opposite strand of DNA. Frameshifting mutant alleles are shown from sequencing
sub-cloned PCR products. H) KEAP1-deficient Cells were Functionally Tested by Challenging with an
Oxidant (H2O2). Cell viability was measured using MTT assay 24 hours post exposure to increasing
concentrations of H2O2. Error bars show SEM for each measurement. Data are expressed as mean ± SEM.
****P < 0.0001; Student’s t-test.
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Comparison of Methods for Cas9-mediated Genome Editing Using a Reporter System
Genome editing using CRISPR-Cas9 is an exciting field that utilizes the cells natural
homology directed repair response to incorporate exogenous pieces of DNA into the genome
(Ran et al., 2013). However, genome editing in the past has been reported at very low rates
meaning that researchers had to screen many clones to find a successfully edited population
(Bialk et al., 2015; Bialk et al., 2016). We wanted to improve not only the efficiency of genome
editing, but also the accessibility, by optimizing CRISPR-Cas9 genome editing using lipidmediated transfection.
To best quantify the effectiveness of editing, we again used the HEK 293 FlpIn cell line,
but inserted an EGFP lacking the ATG start codon into the FRT site. This cell line is GFP
negative, but becomes GFP positive with the successful insertion of an ATG at the genome
editing site (Figure 5A). We also created an HEK 293 FlpIn DATG EGFP Cas9 cell line that
stably expresses Cas9 protein. Using these two cells lines we compared knock-in efficiency
using plasmid to express Cas9 and gRNA, RNP, and gRNA only into stably expressing Cas9
cells. In all of these transfections a single stranded oligonucleotide containing the ATG to be
inserted and 30bp homology arms was also included (Figure 5B). To verify the effectiveness of
the transcribed gRNA, an in vitro Cas9 digestion was performed prior to transfection. A PCR
amplified region of a plasmid containing DATG EGFP was used as a template and incubated
with Cas9 and a gRNA directed to cut DATG EGFP 5 bp from the ATG insertion site. The in
vitro digestion showed successful cutting, so we decided to move forward with knock-in
transfections (Figure 5B).
To confirm that our reporter system worked and to determine how long it took for GFP to
accumulate to detectable levels, we first tried all transfections without any selection reagent and
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examined the cells for fluorescence. We were able to see a few GFP positive cells after only 24
hours indicating that the knock-in was successful. We determined that waiting 5 days post
transfection allowed the cells enough time to accumulate GFP to maximize fluorescence. The
first rounds of transfection without selection did have successful knock-in, but at a low
efficiency as we expected due to the results of our knock out experiments. Since our goal was to
optimize efficiency of knock-in, we decided that co-transfection of a selectable marker would be
key to increasing the knock-in percentage.
We next tried transfection followed by puromycin selection. The px459v2 plasmid used
already confers puromycin resistance, so for the RNP and RNA only transfections we again cotransfected a plasmid expressing puromycin N-acetyl-transferase (PAC). 24 hours after
transfection, puromycin was added for 48 hours. Flow cytometry was performed 5 days post
transfection to measure GFP percentage. A representative of the GFP flow data is shown in
Figure 5C. A GFP population is present after RNP transfection that was not present in the HEK
293 FlpIn DATG EGFP population before transfection (Figure 5C). Puromycin selection greatly
increased the percentage of cells that were successfully edited, showing again that transfection
efficiency is a limiting factor in lipofection mediated Cas9 editing.
We next sought to optimize the amount of donor template that should be transfected
along with plasmid, RNP, or RNA only transfections. Papers have sited varying optimal
concentrations of donor template, so we wanted to determine the ideal concentration for Cas9
editing using lipofection (Lin et al., 2014; Moyer and Holland, 2015). We tried 500 ng, 100ng,
50 ng, and 10 ng of donor template with each of the three methods of Cas9 introduction.
Interestingly the amount of template that produced the best results varied by Cas9 expression
type. Plasmid transfections were best with 500 ng of template, whereas RNP transfections were
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Figure 5. Comparison of Methods for Inserting Exogenous Sequences. A) A Reporter System for
Detection of HDR-mediated Introduction of Exogenous Sequences. A single ∆ATG-EGFP cassette was
inserted at the FlpIn locus in HEK 293 cells. Introducing an ATG at the 5` end of the cassette results in
GFP positive cells. B) Schematic of Target and Donor DNA and In vitro Digestion with RNP. The
exogenous ATG (red) is shown in the donor. Kozak sequence (underlined), Cas9 cut site (arrow) and
PAM (box) is shown in the target gDNA. In vitro digestion was done using a 1000 bp PCR product of
∆ATG-EGFP. Digestion with RNP results in two 500bp segments. C) Representative Histogram of
Control and Edited Cells Showing the Shift in GFP Fluorescence Five Days Post Transfection. D)
Quantification of the Fraction of GFP Positive Cells After Treatment with Cas9, gRNA, and Donor DNA
Using Different Methods of Introduction (n=3/group). Data are expressed as mean ± SEM. *P < 0.05;
Student’s t-test.

most effective with 50 ng of template, and RNA only transfections produced the best results with
10 ng of template (Data not shown). This variation in concentration may be due to the different
methods of Cas9 expression.
The best concentration for each of the transfection methods is compared in Figure 5D.
Transfection of gRNA only into Cas9 expressing cells had the overall highest editing rate,
however, very few cells survived selection in this method. We had to let the cells grow out for 7
days in order to get enough cells to measure through flow cytometry and only the transfections
containing small amounts of donor template had any living cells. This means that although there
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are a high percentage of edited cells in RNA only transfections, it may not be the most effective
method due to the few number of cells surviving selection. Again RNP showed a high level of
editing and more cells were able to survive selection making this a more reasonable approach for
knock-ins.

Larger Knock-ins Using a Reporter System
One benefit of the reporter system we created is the ability to knock-in a variety of tags to
the genome editing site. This is a distinct advantage over previous GFP reporter systems that
only express GFP with the correction of one base pair (Bialk et al., 2016; Richardson et al.,
2016; Rivera-Torres et al., 2017). We decided to attempt to knock-in two commonly used tags,
FLAG and RFP at the DATG site (Figure 6A). With knock-in of either tag the cells also express
GFP allowing for easy quantification of knock-in percentage.
The ATG and FLAG donor templates were single stranded oligonucleotides with 30bp
homology arms. The RFP template was created through PCR and was therefore double stranded.
We ordered primers to amplify RFP that also contained 35bp of homology to the knock-in site in
DATG. Amplifying RFP through PCR to create a donor template was quick, effective, and
inexpensive. This technique greatly simplifies the insertion of large pieces of DNA since the
cloning of donor templates with long homology arms can take days or weeks.
For all experiments we used RNP transfections using the ideal conditions found in our
previous optimization. All knock-in experiments were successful, however, as the size of the
insert went up, the efficiency of knock-in decreased (Figure 6B). We also did a western blot for
GFP to confirm the expression of GFP (Figure 6C). Interestingly we found that some cells
expressed GFP with RNP transfection alone. We confirmed that an 8bp deletion would result in
an in frame ATG start codon. Images of cells edited with RFP donor template also show that all
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RFP positive cells are also GFP positive, however, there are a number of GFP positive cells
without RFP expression. Overall we found that knock-in of larger templates is possible,
however, the efficiency may go down as the size of the insert increases.

Figure 6. Introduction of Epitope Tags and Fluorescent-protein Tags Using RNP Transfection. A)
Schematic of Donor Templates that were Inserted into our Reporter Construct. Size of the inserted
DNA is shown on the right. Kozak sequence (underlined), Cas9 cut site (arrow) and protospacer
adjacent motif (PAM; box) is shown in the target gDNA. B) Fraction of GFP Positive Cells After RNP
Transfection with Different Donors (n=3/group). C) Western blot with Anti-GFP Antibody Showing
GFP and Modified-GFP After Editing. D) Representative Immunofluorescence Images of Edited Cells
Showing Co-localization of GFP and RFP Fluorescence. Scale bar is 100 µm. Data are expressed as
mean ± SEM. *P < 0.05; Student’s t-test.
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Forward Genetic Screen for Telomere Length Maintenance Genes

Knockout of TERT Protects Cells from MT-hTR-AU5 Transduction
In order to design a forward genetic screen in which we could identify new genes
involved in telomere length maintenance, we first needed to find a proper selection agent. Recent
publications described MT-hTR-47A and MT-hTR-AU5 viruses which are predicted to add
mutated telomere sequences to the end of chromosomes and have been shown to cause cell
senescence and apoptosis (Stohr and Blackburn, 2008; Stohr et al., 2010). Shelterin recognizes
and binds to wild type telomere sequence, so addition of mutated telomere sequence is predicted
to disrupt telomere-shelterin binding and trigger a DNA damage response. Before attempting a
forward genetic screen we tested if these viruses caused cellular senescence or apoptosis and if
disrupting the telomere length maintenance pathway could rescue transduced cells.
We first sought to verify the toxicity of MT-hTR-47A and MT-hTR-AU5 in cell lines
routinely used on our lab. Unexpectedly, HEK 293 and HeLa cells did not appear to be sensitive
to the template mutants and grew readily even in the presence of high viral titers (data not
shown). We found that the toxicity of these viruses varies by cell line and that the addition of
mutated telomere templates was most detrimental to LOX melanoma cells (a telomerase positive
human cancer cell line)(Goldkorn and Blackburn, 2006; Stohr and Blackburn, 2008). We
compared MT-hTR-47A and MT-hTR-AU5 and found MT-hTR-AU5, which is predicted to add
“TATATA” to the end of telomeres, to be more lethal to LOX cells and therefore decided to
move forward using MT-hTR-AU5.
To show that disruption of the telomere length maintenance pathway could protect
against MT-hTR-AU5 transduction, we tested the survival of LOX cells transduced MT-hTRAU5 in which telomerase reverse transcriptase (TERT) had first been knocked out. After cloning
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LOX Cas9 cells, we transduced a population of cells with a lentivirus encoding a gRNA directed
to TERT and then selected with puromycin 48 hours after the addition of virus. We hypothesized
that cells that were deficient for TERT would be resistant to MT-hTR-AU5 transduction since
the knockout of TERT disrupts the addition of new telomere sequence. After multiple trials we
found that it was important to use cells as quickly after selection for TERT knockout since cells
lacking TERT have a growth disadvantage. MT-hTR-AU5 and hTR-WT, which codes for wild
type telomere sequence, were added to LOX Cas9 cells and TERT knockout LOX Cas9 cells.
Both MT-hTR-AU5 and hTR-WT viruses were packaged from a lentiviral plasmid that also
expresses GFP, so all transduced cells also expressed GFP. In order to measure the number of
living cells containing virus, the GFP percentage was measured through flow cytometry every 23 days post transduction. As can be seen in Figure 7A, the wild type virus had no effect on the
transduced cells and the GFP percentage remained constant throughout the experiment.
However, we saw varying results with MT-hTR-AU5 viral transduction. The LOX Cas9 cells
containing the virus were nearly gone by two weeks post infection reproducing previously
reported data (Stohr and Blackburn, 2008; Stohr et al., 2010). On the other hand, TERT knockout
LOX cells had an initial drop in GFP percentage, but then the level of GFP stayed constant
around 35-40% (Figure 7A).
We hypothesized that this initial drop in GFP percentage in the TERT knockout cells may
have been due to incomplete knock out of TERT in a portion of the population. In order to
confirm our prediction, we sorted the TERT knock out cells into GFP positive and GFP negative
groups. We isolated 3 clones from each group and sequenced TERT in the GFP positive clones.
These clones were significant because they were able to survive despite expressing MT-hTRAU5. The sequencing of these clones showed frameshifting indels in all alleles, supporting our
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theory that complete knock out of TERT protects cells from the MT-hTR-AU5 virus (Figure
7B). We also performed a Telomerase Repeat Amplification Protocol (TRAP) assay to show the
activity of telomerase in these groups of cells. The three clones in the GFP positive group
showed no telomerase activity, however, two of the three clones in the GFP negative group
showed telomerase activity (Figure 7C). This confirmed our initial thought that transduction of
the lentivirus containing a gRNA to TERT did not result in complete knock out of TERT in the
entire population, which may explain the initial dip in GFP percentage in the TERT knockout
group. Most importantly, we showed that cells that had a complete knockout of telomerase
activity were able to survive transduction of MT-hTR-AU5. We concluded that MT-hTR-AU5
could be used in a forward genetic screen to identify genes involved in telomere length
maintenance.
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Figure 7: Knockout of TERT can Protect from MT-hTR-AU5 Infection. A) Transduction of WT-hTR Shows No
Effect on LOX Cas9 and LOX Cas9 lg-hTERT cells. LOX Cas9 cells tranduced with AU5-hTR are almost
completely dead 14 days after infection. LOX Cas9 cells that first had hTERT knocked out show some cell
death initially, but remain 35-40% GFP positive after infection with AU5-hTR. B) Sequencing of Clones that
Remained GFP Positive After MT-hTR-AU5 Transduction Show Detrimental Mutations to hTERT. One
allele is shown from each of the clones sequenced as a representation of sequencing results. In each clone
all alleles were mutated. C) GFP Positive Clones also Show No Telomerase Activity in TRAP Assay. 2 of the
3 clones from the GFP negative population show telomerase activity despite having received a virus
containing a gRNA directed to TERT.
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Forward Genetic Screen Identifies ZNF827
Following our positive preliminary results, we decided to move forward in the design of
our forward genetic screen. Each step in the process took many rounds of optimization to
determine the optimal conditions for the screen. The overall flow for our final forward genetic
screen is depicted in Figure 8A.
Our first attempt at a forward genetic screen was unsuccessful. We used the MT-hTRAU5 virus cloned into a viral plasmid containing hygromycin resistance, however, the
hygromycin selection was not completely effective which confounded our results. We also used
the Human GeCKO CRISPR library A and library B, which was developed before current
understanding of the rules that determine gRNA activity meaning that it is not as effective as
more recently developed libraries (Doench et al., 2016a; Doench et al., 2014). Another difficulty
in our first screen attempt was that we transduced the GeCKO libraries at an MOI 0.1 to ensure
that each cell only got one gRNA and therefore only knocked out one gene. There are ~120,000
gRNAs in the combined GeCKO library so in order to have 100 fold representation of each
gRNA and transduce at an MOI of 0.1 we had to begin the experiment with 120 million cells. In
order to ensure that we maintained our library representation throughout the experiment we
passaged a minimum of 16 million cells. Overall the first attempt was not successful and we did
not see any likely candidate genes emerge from the sequencing results. Learning from this
experience we decided to try again with many adjustments.
In our second screen we used the newer Human Brunello CRISPR knockout pooled
library (Broad GPP), which was designed to be more effective than previous CRISPR libraries
by following the recently developed gRNA design rules (Doench et al., 2016b; Doench et al.,
2014). This time we also decided to transduce the cells with the Broad GPP library at an MOI of
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3 which allowed us to passage fewer cells and through our analysis still determine which gRNAs
were enriched. We again allowed the cells to grow for a few days following puromycin selection
and then added the GFP expressing MT-hTR-AU5 at an MOI of 10, which was the MOI used for
our preliminary studies. The cells were then plated lightly and allowed to grow for 15 days. In
the past we showed that 15 days was sufficient to cause a significant reduction in transduced
cells. At this point we sorted the cells into GFP positive and negative populations. We replated
both populations and allowed the cells to grow for another 15 days. At this time, we collected
genomic DNA from the GFP negative cells and resorted the GFP positive cells and collected
genomic DNA directly from the GFP positive population following the sorting.
Once genomic DNA was collected, we performed two PCRs. The first PCR was used to
amplify gRNAs and the second PCR was used the add illumina bar codes and adapters to the
PCR products from the first PCR. The DNA from the GFP negative population received a
different barcode from the DNA from the GFP positive population so that we could compare the
results after sequencing. Afterwards qPCR was performed in order to determine accurate
concentrations of DNA in each of the barcodes. All of the barcodes were then mixed and qPCR
performed again to ensure the concentration of DNA was correct for deep sequencing. The
samples were run on an illumina miseq at John Hopkin’s University.
The results from the deep sequencing were split into barcodes using custom Pearl script,
then the gRNA sequences were aligned to genes through Bowtie, and the results were analyzed
through MaGeCK. We looked for gRNAs that were significantly enriched in the GFP positive
group when compared to the GFP negative group. We also took into account how many gRNAs
to the gene were found to be enriched. The GPP library has 4 gRNAs to each of the genes
included in the library, so when more of the gRNAs are found to be enriched in the treatment
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group, the more likely that candidate gene is to be a real hit. MaGeCK takes all of that
information into account and ranks the genes in order of their positive selection score. The top 7
candidate genes can be seen in table 2. A gene enrichment plot for all of the genes included in
the study is also shown in Figure 8B. The top 7 genes are indicated on the plot and their relation
to the rest of the candidate genes can be seen.
From the results of this screen we decided to focus on the genes that had more than one
gRNA enriched in the treatment sample as that increases the likelihood that the gene is a real hit.
Of the top 7 genes, ZNF827, TMEM8C, GAD2, and OMG all had 3 gRNAs enriched in the
treatment group. These 4 genes were all potential genes of interest, however, we decided to first
focus on ZNF827. Not only was ZNF827 the top hit from the screen, but it has also been
localized to the telomere (Conomos et al., 2014).
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Figure 8: Forward Genetic Screen Experimental Design and Results. A) The Overall Flow of the Forward
Genetic Xcreen. Cells are first transduced with the CRISPR library. Flowing selection cells are then
transduced with MT-hTR-AU5 and allowed to grow for 15 days before sorting. The GFP positive cells were
actually grown for another 15 days and resorted. Genomic DNA was then collected from the cells and sent
for deep sequencing. B) Gene Ranking Shown as the –Log10 p-value of the Positive P-value Score Calculated
by MaGeCK. The genes that had 3 gRNAs enriched in the treatment group are shown in red. The genes that
only had 1 gRNA enriched in the treatment group are shown in blue.
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Table 2: Top Positive Ranked Genes from Forward Genetic Screen
Gene

Positive Rank

P-value

Enriched
gRNAS

Gene Function

ZNF827

1

6.50E-05

3

YES1

2

7.80E-05

1

Zinc finger protein of unknown
function
Tyrosine kinase- proto-oncogene

TMEM8C

3

1.73E-04

3

Mediates myoblast fusion

ATXN1L

4

2.22E-04

1

GAD2

5

3.53E-04

3

HECTD3

6

3.78E-04

1

OMG

7

4.45E-04

3

Chromatin binding factorrepresses notch signalling
Glutamic acid decarboxylaseautoantigen in insulin dependent
diabetes
Transfers ubiquitin to targeted
substrate for degradation
Cell adhesion molecule found in
the brain

ZNF827 Verification
ZNF827 is a zinc finger nuclease with little known about its function (Conomos et al.,
2014; Pickett and Reddel, 2015). It has been reported to be localized to the telomere and recruit
NuRD in association with alternative lengthening of telomeres (Conomos et al., 2014; Pickett
and Reddel, 2015). Mutations in ZNF827 have also appeared in multiple genome-wide
association studies for various conditions, however, no causal link has ever been shown
(Chambers et al., 2011; Jiang et al., 2015; Kim et al., 2011; Sio et al., 2017). Because it was the
top hit in our forward genetic screen as well as its localization to telomeres this became our top
gene moving forward.
In order to confirm that ZNF827 knockout would result in protection from the MT-hTRAU5 virus, we cloned a gRNA directed to ZNF827 in to lentiviral plasmid. After transduction of
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LOX Cas9 cells with the lentivirus containing the ZNF827 gRNA and selection with puromycin,
we cloned the cell population to isolate a clone with confirmed knockout of ZNF827. In our
screening we identified two clones (clone 10 and clone 12) that had deleterious mutations in both
alleles of ZNF827 (Figure 9A).
In order to test the resistance of ZNF827 knockout cells to the MT-hTR-AU5 virus, we
again transduced LOX cells, TERT knockout LOX cells, and the ZNF827 knockout LOX cells
with MT-hTR-AU5. We performed the transduction in triplicate and measured the GFP
percentage through flow cytometry (Figure 9B). As expected, approximately two weeks after
transduction, the wild type LOX cells had a low percentage of GFP positive cells remaining
(Figure 9B). Unexpectedly, TERT knockout LOX cells also had a reduced number of GFP
positive cells (Figure 9B). New TERT knockout cells have to be generated before each trial
because cells have a limited number of divisions after knockout of telomerase function. During
this knockout of TERT and selection there may have been a lower percentage of cells that fully
disrupted telomerase function. We previously showed that some cells retained telomerase
activity after transduction of the gRNA to TERT indicating that the a portion of cells in this
population may have had telomerase function
LOX ZNF827 knockout clone 10 showed significantly higher GFP percentages than wild
type LOX cells at 6, 9, and 13 days post-transduction. The cells from this population appear to
have some level of resistance to the MT-hTR-AU5 virus indicating that the knockout of ZNF827
is preventing the addition of mutant telomere sequence. However, LOX ZNF827 knockout clone
12 showed little resistance to MT-hTR-AU5 and only showed a significance difference from the
control cells on day 6. Clone 12 sequencing results showed two mutations one of which was a
27bp deletion. This is a large deletion and so we initially assumed there would be no ZNF827
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activity, however, since that is an in frame deletion there is a chance that these cells retained
some ZNF827 activity, which may explain the different results between the two ZNF827
knockout clones.

A

GFP %

B

Days Post Transduction
Figure 9: Verification of ZNF827. A) Sequencing Results From Two Isolated Clones. Both clones
showed deleterious mutations in both alleles. B) Graph Showing Results of MT-hTR-AU5 transduction
of Wild Type LOX cells, TERT KO LOX cells, and two ZNF827 KO LOX clones. ZNF827 KO clone 10
showed significant differences in GFP percentage from wild type LOX cells on days 6, 9, and 13(pvalues: 0.0025913, 0.0007739, 0.0004214 respectively). ZNF827 KO clone 12 only showed a significant
difference from wild type LOX cells on day 6 (p value: 0.0034659).
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DISCUSSION
The use of CRISPR-Cas9 for genome editing in laboratory settings has become an
invaluable tool. It can be used to knock-out genes, modify gene expression, perform forward
genetic screens, knock-in exogenous DNA such as fluorescent tags or selectable markers, along
with many other uses. However, there was a need for further optimization of delivery of Cas9
components to make it more widely available. Many of the techniques used to effectively
introduce Cas9 components either require specialized equipment or have additional biosafety
requirements. The optimization of CRISPR-Cas9 using lipid-mediated transfection methods to
introduce Cas9 and a gRNA will allow for more widespread use of this valuable technique.
We found through our optimization that ribonucleoprotein (RNP) transfection was the
most efficient method for gene knockout in our reporter system. RNP transfection worked well
for knockout of TERT, however, it interestingly did not work for KEAP1 knockout. Recent
studies have shown that the sequence of the gRNA can actually affect transcription and stability
of gRNAs in cells (Haeussler et al., 2016; Moreno-Mateos et al., 2015). Therefore, KEAP1
gRNA may have been readily degraded when transfected in RNP form, however, when
expressed from a plasmid with a strong U6 promotor there may have been enough gRNA to
effectively cut KEAP1. This shows that although RNP transfection was effective, it may not
work in every situation.
RNA only transfection into stably expressing Cas9 cells had highest knock-in percentage
using our HEK 293 FlpIn DATG EGFP reporter system, however, very few cells survived
selection. Despite the high percentage of edited cells, this makes RNA only transfections less
promising. RNP lipofection also had a high level of edited cells and many more cells survived
selection making RNP transfection overall more efficient for knocking-in exogenous DNA.
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RNP transfection also has many benefits that make the use of CRISPR-Cas9 more
efficient. One preparation of Cas9 protein will provide enough protein for many transfections.
Also gRNA can be transcribed in one day as opposed to the many days of cloning required to
create plasmids. The gRNA can also be tested functionally in vitro prior to cell transfection
increasing the likelihood that genome editing will be successful in cells. Finally, the half-life of
donor DNA in cells is short, only 50-90 minutes, so delivering pre-assembled functional RNP
will allow Cas9 to cut faster and increase the chances of homology directed repair using the
donor DNA template (Lechardeur et al., 1999; Woolf et al., 1990).
Interestingly we found that the optimal amount of donor template for exogenous DNA
insertion differed with the various methods of introducing Cas9 and gRNA. This variation in
concentration may be due to the different methods of Cas9 expression. With plasmid
transfections, genome editing cannot take place until Cas9 is transcribed and translated from the
plasmid which may require higher levels of donor template to be co-transfected so it is not
degraded by the time Cas9 is functional. On the other hand, RNP is preassembled and ready to
cut the DNA at the time of transfection and therefore may not require as much repair template to
be present. RNA only transfections seemed the most detrimental to cells and high levels of donor
template also reduced cell viability post selection, which may explain the low repair template
amount in RNA only transfections.
We also found that short homology arms could be used effectively in both single and
double stranded repair templates even with large knock-ins. This is important because it can
greatly reduce the cloning time and cost required to create repair templates. This confirms the
findings of previously published papers using short homology arms for donor templates (Liang et
al., 2017; Natsume et al., 2016; Song and Stieger, 2017). We further showed that double stranded

36

templates with short homology arms can be created through PCR using primers ordered that
contain the homology arms and a plasmid that contains the exogenous DNA insert. This method
of creating large donor templates is fast, inexpensive, and easy to perform. This optimization
using widely available resources should make CRISPR/Cas9 genome editing more accessible to
all labs.
The use of CRISPR-Cas9 in a forward genetic screen allowed us to identify new potential
genes involved in the telomere length maintenance pathway. In recent years, mutations in
telomere related genes have been shown to cause a spectrum of diseases called the telomere
syndromes, with the most prevalent disease being pulmonary fibrosis (Alder et al., 2008; Alder
et al., 2015; Armanios and Blackburn, 2012; Armanios et al., 2007). As more telomere genes are
linked to pulmonary fibrosis the number of familial pulmonary fibrosis cases with diagnosed
genetic causes has increased. Now 25% of familial pulmonary fibrosis cases have been linked to
mutations in telomere related genes, however, more than half of familial pulmonary fibrosis
cases still have an unknown genetic cause (Alder et al., 2011; Alder et al., 2015; Fingerlin et al.,
2013; Hoffman et al., 2016; Kropski et al., 2016; Petrovski et al., 2017). There may be more
telomere related gene mutations contributing to pulmonary fibrosis that have not yet been
discovered.
We decided to perform a screen to identify new genes involved in the telomere length
maintenance pathway. Finding new components of this pathway will lead to a better
understanding of the molecular mechanisms of telomere lengthening and could potentially aid in
diagnosis of patients with telomere syndromes as well as provide avenues for future research.
Our screen used the MT-hTR-AU5 virus, which is predicted to add the mutated telomere
sequence “TATATA”, to screen for cell populations missing a necessary component of the
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telomere length maintenance pathway (Stohr and Blackburn, 2008; Stohr et al., 2010). MT-hTRAU5 causes cell senescence or apoptosis by compromising the binding of shelterin to the
telomere and therefore initiating a DNA damage response within the cell. If the CRISPR library
knocks out a gene essential to the addition of new telomeric sequence, the mutated telomere
sequence will not be added to the end of the chromosome protecting the cell from a damage
response and subsequent cell death.
Of the top 7 candidate genes from our screen, 4 genes had 3 gRNAs enriched in the
treatment group and 3 genes only had 1 gRNA enriched. We therefore decided to focus on the
genes with more than one gRNA enriched. Our main interest was the top ranked gene, ZNF827,
which is a zinc finger protein. There is not much known about the function of ZNF827, however,
a previous publication localized it to the telomere in conjunction with alternative lengthening of
telomeres (Conomos et al., 2014). However, the enrichment of ZNF827 in the treatment group in
our screen indicates that it may actually be playing a role telomere length maintenance.
In order to verify that ZNF827 could protect from MT-hTR-AU5 infection we created
ZNF827 knockout cell lines in LOX cells and transduced with MT-hTR-AU5. LOX ZNF827
knockout clone 10 cells showed a significant increase in GFP percentage following transduction
with MT-hTR-AU5. This indicates that knockout of ZNF827 is disrupting the telomere length
maintenance pathway and allowing for cell survival following infection with a virus containing
mutated telomerase RNA. Interestingly LOX ZNF827 knockout clone 12 did not show this same
protection from MT-hTR-AU5 transduction. The sequencing results of clone 12 indicate that one
allele contained a 27bp deletion, which is an in frame deletion. We assumed a deletion that large
would disrupt ZNF827 function, however, the results of the experiment indicate that there may
be different expression levels of ZNF827 in clone 10 and clone 12.
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The finding that ZNF827 may be linked to telomere length maintenance holds enormous
research potential. Further work needs to be done to elucidate the exact role ZNF827 plays at the
telomere which will give a clearer understanding of how new telomere sequence is added. Future
research also need to be done to investigate potential links between ZNF827 mutations and
clinical manifestations such as telomere syndromes. Overall, these findings could have far
reaching effects both in research and clinical applications.
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Table S1: Supplemental Table of Primers Oligonucleotides Used for Screening and
Cloning.

Primers for Double
Stranded Repair
Templates

Sequence (5’-3’)

Description

TagRFP_knockin_Fwd

AAGCTTGGTACCGAGCTCGGATCC GCCACC ATGGTGTCTAAGGGCGAAGAG

TagRFP_knockin_Rev2

CCCGGTGAACAGCTCCTCGCCCTTGCTCAC GCCAGAGCCGCCGCC

Primers for IVT
template
T7_GFP_sgRNA_1

Sequence (5’-3’)

Template for RFPlinker knock-in with
35bp homology
arms
Description

TGTAATACGACTCACTATAGGGGCGAGGAGCTGTTCACCGGTTTTAGAGCTAG
AAATAGC

gRNA used for GFP
knock out

T7_GFP_sgRNA_3

TGTAATACGACTCACTATAGGGATCCGCCACCGTGAGCAAGTTTTAGAGCTAG
AAATAGC

T7_hTERT-RT_sgRNA

TGTAATACGACTCACTATAGGGCCAGGGCCTCGTCTTCTACAGTTTTAGAGCTA
GAAATAGC

gRNA used for
∆ATG-EGFP cutting
and knock-in
gRNA used for
hTERT knock out

T7_KEAP1_sgRNA

TGTAATACGACTCACTATAGGGCCGCAGCCCGTTGGTGAACAGTTTTAGAGCT
AGAAATAGC

sgRNA_Rev

AAAAAAGCACCGACTCGGTGCCACT

Oligos for px459v2
plasmid construction
GFP_sgRNA_1_top

Sequence (5’-3’)

Description

CACCGGGGCGAGGAGCTGTTCACCG

Ligated into
px459v2

GFP_sgRNA_1_bottom

AAACCGGTGAACAGCTCCTCGCCCC

GFP_sgRNA_2_top

CACCGCAGCTCCTCGCCCTTGCTCA

GFP_sgRNA_2_bottom
Keap1_CRISPR_top

AAACTGAGCAAGGGCGAGGAGCTGC
CACCGCCGCAGCCCGTTGGTGA

Keap1_CRISPR_bottom

AAACTGTTCACCAACGGGCTGC

Single Stranded Repair
Templates
GFP_ssRepair30

Sequence (5’-3’)

Description

AAGCTTGGTACCGAGCTCGGATCCGCCACCATGGTGAGCAAGGGCGAGGAGC
TGTTCACCGGG

deltaATG_GFP_FLAG_s
sdonor

AAGCTTGGTACCGAGCTCGGATCCGCCACCATGGATTACAAAGACGATGACGA
TAAGGTGAGCAAGGGCGAGGAGCTGTTCACCGGG

Screening Primers

Sequence (5’-3’)

ATG only repair
template with 30bp
homology arms
FLAG-ATG repair
template with 30bp
homology arms.
Description

hTERT_seq_fwd1.1
hTERT_seq_Rev1
Keap1_scrn_fwd1
Keap1_scrn_rev1

GCGTGCCCTGGGACG
TATGGTTCCAGGCCCGTTCG
TTGGCATCATGAACGAGCTG
TAGGCGAATTCAATGAGGCG

gRNA used to try
RNP knock out of
Keap1

For hTERT knock
out screening
For Keap1 knock
out screening
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